Table 6.

Recommendations on supportive care in cancer patients with COVID-19.

Population	Intention	Intervention	SoR	QoE	Reference
Cancer patients, uninfected [0] or with COVID-19 [1–9], with vitamin D deficiency	To improve clinical outcome in case of COVID-19	Vitamin D supplementation	B	IIt	[107]
Cancer patients, uninfected [0] or with COVID-19 [1–9], without vitamin D deficiency	To improve clinical outcome in case of COVID-19	Vitamin D supplementation	D	IItr	[108,109]
Cancer patients with COVID-19 – ambulatory, mild [1–3]	To prevent thromboembolic complications	Low-dose LMWH	C	III	[110]
Cancer patients with COVID-19 – hospitalized, moderate to severe [4–9]	To prevent thromboembolic complications	Low-dose LMWH	A	IIt	[111,112]
Cancer patients with COVID-19 – hospitalized, moderate [4–5] plus additional risk factors	To prevent thromboembolic complications and reduce mortality	Therapeutic anticoagulation	B	IIt	[[112], [113], [114], [115]]
Cancer patients with COVID-19 – hospitalized, severe [6–9]	To prevent thromboembolic complications and reduce mortality	Routine intermediate-dose LMWH	D	IIt	[113,116]
Cancer patients with COVID-19 – hospitalized, severe [6–9]	To prevent thromboembolic complications and reduce mortality	Routine therapeutic anticoagulation	D	IIt	[112,117,149]

COVID-19, coronavirus 2019; LMWH, low-molecular-weight heparin.